NDANASALPOWDER
Approved
Apr 2025
Lifecycle
Launch
Competitive Pressure
0/100
Mechanism of Action
5-HT 1Dα and 5-HT 1Dβ receptors. The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effects at 5-HT 1D receptors.
Indications (3)
Loss of Exclusivity
LOE Date
Oct 12, 2041
190 months away
Patent Expiry
Oct 12, 2041
Exclusivity Expiry
Apr 30, 2028